Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC, a biotechnology firm, has partnered with Awakn Life Sciences Corp. to conduct groundbreaking research at the University of Nottingham, aimed at developing new mental health therapeutics for conditions like PTSD. The research focuses on evaluating aminoindane compounds for their ability to enhance social cognition and pro-social behaviors in rodent models. Results from the two-month study are anticipated by the end of 2024, marking a critical step in addressing trauma-related mental health disorders.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
